Funding-DHHS--Adjuvant
Discovery Program; October 10, 2013
Agency
Department
of Health and Human Services
Description
The
National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health (NIH) and other agencies in the Department of Health and
Human Services (DHHS) support extramural research to develop new products to
protect the public from the health consequences of biological agents that might
be used in acts of bioterrorism and from emerging and re-emerging diseases,
such as West Nile Virus, multi-drug resistant Tuberculosis and Dengue
Fever. The biological agents deemed to pose the greatest threat to
civilian populations are prioritized in the NIAID Emerging and Re-emerging
Infectious Diseases list, which is available at:
http://www.niaid.nih.gov/topics/emerging/pages/list.aspx.
NIAID also contributes to meeting the goals for host defense described in the
NIAID Strategic Plan for Biodefense (http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/Documents/biosp2007.pdf)
by supporting the development of new vaccine adjuvants that stimulate stronger,
more protective immune responses against NIAID Emerging and Re-emerging
Infectious Diseases. In addition, NIAID supports research to develop
vaccines against infection by the HIV-1 virus and against the development of
AIDS including the study of adjuvants that might potentiate the induction of
protective immunity.
Announcement
Number:
BAA-NIAID-DAIT-NIHAI2013168
Closing
Date:
Oct 10, 2013 3:00 pm Eastern
Link
to Full Announcement
https://www.fbo.gov/?s=opportunity&mode=form&id=842712fe9dcd4950a515287d512f3cb6&tab=core&_cview=0
Contact
Information
Maribel
Miranda,
Contract
Specialist
Phone:
3014517457
Fax:
3014020972